Besifovir
- Generic Name
- Besifovir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N5O4P
- CAS Number
- 441785-25-7
- Unique Ingredient Identifier
- 4PLG22CQUU
Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT04249908
Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate
- Conditions
- Tenofovir Disoproxil FumarateBesifovir Dipivoxil MaleateHepatitis B
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 152
- Registration Number
- NCT04202536
- Locations
- 🇰🇷
Korea University Medical Center, Ansan, Kyounggi-do, Korea, Republic of
Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 146
- Registration Number
- NCT02792088
- Locations
- 🇰🇷
Severance Hospital of Yonsei University, Seoul, Korea, Republic of
Phase 3 and Extensional Study of Besifovir
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 197
- Registration Number
- NCT01937806
- Locations
- 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Medical Center, Seoul, Korea, Republic of
🇰🇷Wonju Sevrerance Christian Hospital, Wonju, Kangwon-do, Korea, Republic of
Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 115
- Registration Number
- NCT01242787
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
🇰🇷Severance Hospital of Yonsei University and other 8 sites in Korea, Seoul, Korea, Republic of
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 65
- Registration Number
- NCT00895596
- Locations
- 🇰🇷
Korea University Medical Center, Seoul, Korea, Republic of
🇨🇳Queen Mary Hospital, Hong Kong, China
🇰🇷Severance Hospital of Yonsei University, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.